GlobalRPh Renal Dosing Masterv6.8
Product-specific reference

Brinzolamide 1% ophthalmic suspension (Azopt)

Local official-label summarySource retrieved 2026-10-02See the evidence for this drug2 sources available - open source summaries, references and comparisons

brinzolamide / Azopt / brinzolamide ophthalmic

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Before use: Brinzolamide 1% ophthalmic suspension (Azopt)

Single-ingredient ophthalmic suspension only; a topical route does not remove the severe-renal-impairment restriction.

Before applying: Check the exact eye-drop ingredients, CrCl and oral carbonic-anhydrase co-therapy; do not extrapolate to Simbrinza.

Evidence for this qualification

Selected source reconciliation only; independent clinician adjudication pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Brinzolamide 1% ophthalmic suspension (Azopt) - selected label sections

Product / population
Single-ingredient AZOPT brinzolamide 1% ophthalmic suspension (10 mg/mL). Not brinzolamide/brimonidine (Simbrinza).
Renal measure
Creatinine clearance (CrCl), mL/min; not an assumption that all eye drops are safe in kidney failure.
Source revision
06/2023
Retrieved
2026-10-02 (not the revision date)

The official product label and its RX mirror are one underlying evidence family, not two independent clinical validations. Confirm the current exact product label before prescribing.

Renal guidance and important limits

Limits that apply to these rows

Systemic absorption can occur with topical use. Consider sulfonamide hypersensitivity and additive carbonic-anhydrase effects; concomitant oral inhibitors are not recommended.

This is a suspension: shake before use. Usual labeled ocular administration is one drop in the affected eye(s) three times daily. Do not transfer these instructions to combination products.

Brinzolamide 1% ophthalmic suspension (Azopt) - selected renal instructions
Renal settingSource-specific action and limits
CrCl <30 mL/minNot recommended. Severe impairment was not studied; the drug and metabolite are mainly renally eliminated.
Other renal bands / dialysisNo additional renal dose or dialysis regimen is established by this selected summary.
Read the retained text before reformatting
Renal settingSource-specific action and limits
CrCl <30 mL/minNot recommended. Severe impairment was not studied; the drug and metabolite are mainly renally eliminated.
Other renal bands / dialysisNo additional renal dose or dialysis regimen is established by this selected summary.

Systemic absorption can occur with topical use. Consider sulfonamide hypersensitivity and additive carbonic-anhydrase effects; concomitant oral inhibitors are not recommended.

This is a suspension: shake before use. Usual labeled ocular administration is one drop in the affected eye(s) three times daily. Do not transfer these instructions to combination products.

Source revision: 06/2023 | Retrieved: 2026-10-02. Retrieval date is not the revision date.

Source: https://www.novartis.com/us-en/sites/novartis_us/files/azopt.pdf

Scope: Selected renal sections summarized locally. Not a complete monograph or independent clinical approval. GlobalRPh v6.8.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v6.8

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Brinzolamide 1% ophthalmic suspension (Azopt) - selected label sections

Before using this finding

Check the exact eye-drop ingredients, CrCl and oral carbonic-anhydrase co-therapy; do not extrapolate to Simbrinza.

Dialysis evidence: No dialysis regimen established in selected content

Retrieved: 2026-10-02
Source revision: 06/2023

Renal measure: Creatinine clearance (CrCl), mL/min; not an assumption that all eye drops are safe in kidney failure.

Read this dated source finding
Rxlist

Brinzolamide 1% ophthalmic suspension (Azopt) - RX mirror renal summary

Before using this finding

Check the exact eye-drop ingredients, CrCl and oral carbonic-anhydrase co-therapy; do not extrapolate to Simbrinza.

Dialysis evidence: No dialysis regimen established in selected content

Retrieved: 2026-10-02
Source revision: 06/2023

Renal measure: Creatinine clearance (CrCl), mL/min; not an assumption that all eye drops are safe in kidney failure.

Read this dated source finding
See all retained evidence sources
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

Brinzolamide 1% ophthalmic suspension (Azopt) - selected label sections

Source retrieved 2026-10-02

No dialysis regimen established in selected content

Read the source and its limits

Brinzolamide 1% ophthalmic suspension (Azopt) - RX mirror renal summary

Source retrieved 2026-10-02

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Brinzolamide 1% ophthalmic suspension (Azopt) - selected label sections

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Check the exact eye-drop ingredients, CrCl and oral carbonic-anhydrase co-therapy; do not extrapolate to Simbrinza.

Dialysis evidence: No dialysis regimen established in selected content

Single-ingredient AZOPT brinzolamide 1% ophthalmic suspension (10 mg/mL). Not brinzolamide/brimonidine (Simbrinza).

Renal method: Creatinine clearance (CrCl), mL/min; not an assumption that all eye drops are safe in kidney failure.
Retrieved: 2026-10-02

Read local renal resultOpen original reference
GlobalRPh RX List

Brinzolamide 1% ophthalmic suspension (Azopt) - RX mirror renal summary

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Check the exact eye-drop ingredients, CrCl and oral carbonic-anhydrase co-therapy; do not extrapolate to Simbrinza.

Dialysis evidence: No dialysis regimen established in selected content

Single-ingredient AZOPT brinzolamide 1% ophthalmic suspension (10 mg/mL). Not brinzolamide/brimonidine (Simbrinza).

Renal method: Creatinine clearance (CrCl), mL/min; not an assumption that all eye drops are safe in kidney failure.
Retrieved: 2026-10-02

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

source scope and renal guidance

Before use: Brinzolamide 1% ophthalmic suspension (Azopt)

Single-ingredient ophthalmic suspension only; a topical route does not remove the severe-renal-impairment restriction.

How to use this: Check the exact eye-drop ingredients, CrCl and oral carbonic-anhydrase co-therapy; do not extrapolate to Simbrinza.

Brinzolamide 1% ophthalmic suspension (Azopt) - selected label sectionsBrinzolamide 1% ophthalmic suspension (Azopt) - RX mirror renal summary

Selected source reconciliation only; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source

Brinzolamide 1% ophthalmic suspension (Azopt) - selected label sections

Single-ingredient AZOPT brinzolamide 1% ophthalmic suspension (10 mg/mL). Not brinzolamide/brimonidine (Simbrinza).

Method: Creatinine clearance (CrCl), mL/min; not an assumption that all eye drops are safe in kidney failure.

Renal guidance and important limitsRead this complete source summary
Rxlist source

Brinzolamide 1% ophthalmic suspension (Azopt) - RX mirror renal summary

Single-ingredient AZOPT brinzolamide 1% ophthalmic suspension (10 mg/mL). Not brinzolamide/brimonidine (Simbrinza).

Method: Creatinine clearance (CrCl), mL/min; not an assumption that all eye drops are safe in kidney failure.

Renal guidance and important limitsRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeBrinzolamide 1% ophthalmic suspension (Azopt) - selected label sectionsBrinzolamide 1% ophthalmic suspension (Azopt) - RX mirror renal summary
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The official product label and its RX mirror are one underlying evidence family, not two independent clinical validations. Confirm the current exact product label before prescribing.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://www.novartis.com/us-en/sites/novartis_us/files/azopt.pdf

Exact product and population

Single-ingredient AZOPT brinzolamide 1% ophthalmic suspension (10 mg/mL). Not brinzolamide/brimonidine (Simbrinza).

RDM68-brinzolamide-azopt-be310fdee2 · Source section: Selected primary product label: indications / formulationRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Brinzolamide 1% ophthalmic suspension (Azopt) - selected label sections

Open original reference

Open / share this exact local source

Novartis / AZOPT prescribing information · Single-ingredient AZOPT brinzolamide 1% ophthalmic suspension (10 mg/mL). Not brinzolamide/brimonidine (Simbrinza).

Renal method: Creatinine clearance (CrCl), mL/min; not an assumption that all eye drops are safe in kidney failure.
Source date: 06/2023
Retrieved: 2026-10-02

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Check the exact eye-drop ingredients, CrCl and oral carbonic-anhydrase co-therapy; do not extrapolate to Simbrinza.

Dialysis evidence: No dialysis regimen established in selected content

Selected renal sections summarized locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Limits that apply to these rows

Systemic absorption can occur with topical use. Consider sulfonamide hypersensitivity and additive carbonic-anhydrase effects; concomitant oral inhibitors are not recommended.

This is a suspension: shake before use. Usual labeled ocular administration is one drop in the affected eye(s) three times daily. Do not transfer these instructions to combination products.

Brinzolamide 1% ophthalmic suspension (Azopt) - selected renal instructions
Renal settingSource-specific action and limits
CrCl <30 mL/minNot recommended. Severe impairment was not studied; the drug and metabolite are mainly renally eliminated.
Other renal bands / dialysisNo additional renal dose or dialysis regimen is established by this selected summary.
Read the retained text before reformatting
Renal settingSource-specific action and limits
CrCl <30 mL/minNot recommended. Severe impairment was not studied; the drug and metabolite are mainly renally eliminated.
Other renal bands / dialysisNo additional renal dose or dialysis regimen is established by this selected summary.

Systemic absorption can occur with topical use. Consider sulfonamide hypersensitivity and additive carbonic-anhydrase effects; concomitant oral inhibitors are not recommended.

This is a suspension: shake before use. Usual labeled ocular administration is one drop in the affected eye(s) three times daily. Do not transfer these instructions to combination products.

RDM68-brinzolamide-azopt-139b79c8f0 · Source locator: Sections 2, 3, 5.1, 5.3, 7.1 and 7.2

Source-specific limits

The official product label and its RX mirror are one underlying evidence family, not two independent clinical validations. Confirm the current exact product label before prescribing.

Source identity and provenance
Source family
product_label
Source
https://www.novartis.com/us-en/sites/novartis_us/files/azopt.pdf
Retrieved
2026-10-02
Renal-function method
Creatinine clearance (CrCl), mL/min; not an assumption that all eye drops are safe in kidney failure.
Source date/version
06/2023
Hash meaning
Local authored summary; not source HTML/XML/PDF bytes
Local summary SHA-256
139b79c8f0b7203bd2b49bcf445e2dc06a4ff32c3a9d3fd349dd9884601b68ae
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Brinzolamide 1% ophthalmic suspension (Azopt) - RX mirror renal summary

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Single-ingredient AZOPT brinzolamide 1% ophthalmic suspension (10 mg/mL). Not brinzolamide/brimonidine (Simbrinza).

Renal method: Creatinine clearance (CrCl), mL/min; not an assumption that all eye drops are safe in kidney failure.
Source date: 06/2023
Retrieved: 2026-10-02

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Check the exact eye-drop ingredients, CrCl and oral carbonic-anhydrase co-therapy; do not extrapolate to Simbrinza.

Dialysis evidence: No dialysis regimen established in selected content

Selected renal sections summarized locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

The June 2023 mirror states that AZOPT has not been studied in CrCl below 30 mL/min and is not recommended there. The renal restriction applies to the single-ingredient 1% suspension. Ophthalmic administration does not eliminate systemic sulfonamide or additive carbonic-anhydrase effects.

RDM68-brinzolamide-azopt-25f9790afc · Source locator: Named RX renal impairment, dosage and renal-warning sections

Source-specific limits

The official product label and its RX mirror are one underlying evidence family, not two independent clinical validations. Confirm the current exact product label before prescribing.

Source identity and provenance
Source family
product_label
Source
https://globalrph.com/rx-list/azopt-drug/
Retrieved
2026-10-02
Renal-function method
Creatinine clearance (CrCl), mL/min; not an assumption that all eye drops are safe in kidney failure.
Source date/version
06/2023
Hash meaning
Local authored summary; not source HTML/XML/PDF bytes
Local summary SHA-256
25f9790afc3e5e7f059748914036d43ef48fcadbbb80657932b3c6568958208a

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://www.novartis.com/us-en/sites/novartis_us/files/azopt.pdf
Source retrieval
2026-10-02. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
be310fdee28eab18281d90318ce4e44f11b24e40bb594f47f0c9c8e8a21abeed
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report